Sampre Nutritions Limited

Sampre Nutritions Limited

BBSE:SAMPRE
4.80
INR
+0.01
(+0.21%)
0.37EPS
20.42P/E
726.82MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
7.95
5.23
23.39
17.42
16.93
14.88
12.89
9.46
11.99
16.19
9.15
2.99
30.66
4.98
Basic EPS, GAAP
0.11
0.07
0.45
0.23
0.13
0.12
0.17
0.04
0.16
0.15
0.08
-0.91
2.18
0.37
Free Cash Flow per Basic Share
-1.62
-0.55
-1.63
-2.21
-0.33
-2.41
0.62
-1.31
0.57
-1.54
0.09
-0.02
-2.39
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.38
4.45
4.9
5.13
5.26
5.38
5.55
5.59
5.75
7.7
7.73
10.82
11.3
- -
Tangible Book Value per Share
4.38
4.45
4.9
5.13
5.26
5.38
5.55
5.59
5.75
7.7
7.73
10.82
11.3
- -
Basic Weighted Avg Shares
19
19
19
19
19
19
19
19
19
23
27
84
14
95
Sales/Revenue/Turnover
153
101
451
336
326
287
249
182
231
371
251
251
433
473
Operating Margin (%)
4.15
5.27
3.52
5.06
4.79
8.22
9.72
8.9
8.15
6.02
9.11
-23.17
6.3
6.76
Depreciation Expense
12
12
12
13
15
14
15
18
16
18
18
20
20
22
Net Income, GAAP
2
1
9
5
2
2
3
1
3
3
2
-77
31
36
Effective Tax Rate (%)
52.32
38.67
15.08
31.83
49.97
4.21
26.38
30.29
17.3
16.83
52.48
- -
- -
- -
Profit Margin (%)
1.38
1.28
1.9
1.35
0.74
0.81
1.35
0.42
1.33
0.94
0.92
-30.54
7.1
7.53
Working Capital
-8
9
-5
9
30
-31
-25
-5
10
51
38
23
86
- -
LT Debt
4
17
39
68
92
110
108
122
128
107
95
106
128
- -
Total Equity
85
86
94
99
101
104
107
108
111
212
225
909
1,074
- -
Return on Invested Capital (%)
2.01
1.07
5.75
5.65
3.28
8.18
5.78
3.59
4.78
5.28
2.79
- -
- -
- -
Return on Capital (%)
2.01
3.24
9.55
5.95
3.44
7.66
5.89
3.63
5.37
5.2
2.92
- -
- -
- -
Return on Common Equity (%)
2.57
1.52
9.53
4.67
2.42
2.25
3.19
0.7
2.81
2.15
1.06
-13.54
3.1
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
52
- -
LT Borrowings
- -
128
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
103
95
95
Market Capitalization
2,560
1,645
727

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
229
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
133
- -
Inventories
- -
76
- -
Total Current Liabilities
- -
143
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
52
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
43.59%
84.48%
18.13%
Free Cash Flow
94.8%
161.22%
1,654.51%
Net Income, GAAP
-339.43%
-652.76%
-140.1%
Sales/Revenue/Turnover
4.71%
25.5%
72.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
45
73
56
78
251
2026
109
100
74
151
433
2027
148
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.03
0.04
-0.08
-0.85
-0.91
2026
0.08
0.1
0.06
0.14
2.18
2027
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Brahma Kishanchand Gurbani
Full Time Employees
128
Sector
Consumer non-durables
Industry
Food: specialty/candy
Address
Plot No. 133, TSIIC Industrial Estate Hyderabad TS India 501 401
IPO Date
Jan 31, 2002
Business
Sampre Nutritions Limited manufactures confectionery products including éclairs, hard-boiled candies, toffees, powder candies and centre-filled products; the company produces both for multinational clients such as Cadbury India Ltd and its own brands like Candy Nutri, Creme Zone and Just Toffy, with a focus on fortified sugar candies for health-conscious consumers. Incorporated in 1991 and headquartered at Plot No. 133, TSIIC Industrial Estate, Medchal, Telangana, India, Sampre Nutritions operates two manufacturing facilities meeting GMP and drug-quality hygiene standards, serving domestic and international markets including exports. In October 2025, the company enters a three-year manufacturing and supply agreement with Reliance Consumer Products Ltd for nutraceutical and food products expected to generate Rs 12-15 crore annually; it plans to issue 400 Foreign Currency Convertible Bonds aggregating USD 40 million; and recently secures additional manufacturing agreements worth Rs 45 crore while expanding into emerging markets like Egypt and Liberia.